Drug Type Small molecule drug |
Synonyms 1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione, Alloxanthine, DHPP + [6] |
Target |
Mechanism XO inhibitors(Xanthine dehydrogenase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC5H4N4O2 |
InChIKeyHXNFUBHNUDHIGC-UHFFFAOYSA-N |
CAS Registry2465-59-0 |
Start Date26 May 2014 |
Sponsor / Collaborator- |
Start Date19 Jan 2005 |
Sponsor / Collaborator |
Start Date04 Nov 2003 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gout | NDA/BLA | - | - | |
Gout | NDA/BLA | - | - | |
Heart Failure | NDA/BLA | - | - | |
Heart Failure | NDA/BLA | - | - | |
Stomatitis | NDA/BLA | - | - | |
Stomatitis | NDA/BLA | - | - | |
Polycystic Kidney, Autosomal Dominant | Phase 3 | CA | 03 May 2022 | |
Heart failure NYHA class IV | Phase 3 | US | 01 Mar 2003 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |